|
|
5-day change | 1st Jan Change | ||
|
822.08 USD |
-8.55% | -3.05% | +7.97% | |
Published on 05/01/2025 at 11:00
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Exclusive-WHO to back use of weight-loss drugs for adults globally, raises cost issue |
11:00am |
RE |
|
WHO to back use of weight-loss drugs for adults globally, raises cost issue |
11:00am |
RE |
|
Eli Lilly’s strong quarter undercut by CVS move to drop Zepbound coverage |
10:46am |
RE |
|
Eli Lilly’s strong quarter undercut by CVS move to drop Zepbound coverage |
10:46am |
RE |
|
Nasdaq leads gains on Wall Street as Microsoft, Meta surge |
10:29am |
RE |
|
CVS raises profit forecast, to exit Obamacare market as turnaround gains steam |
09:59am |
RE |
|
Sector Update: Health Care Stocks Mixed Premarket Thursday |
09:12am |
MT |
|
Eli Lilly Lowers 2025 Earnings Outlook Despite Stronger-Than-Expected First-Quarter Results |
09:07am |
MT |
|
Wall Street set for strong open as Microsoft, Meta soar |
09:05am |
RE |
|
Sector Update: Health Care |
08:54am |
MT |
|
Stocks Rise Pre-Bell Following Upbeat Microsoft, Meta Results; Investors Await More Tech Earnings |
07:37am |
MT |
|
US stock futures jump as Microsoft, Meta climb after results |
07:29am |
RE |
|
Tech Earnings Drive Wall Street Up Pre-Bell; Asia, Europe Gain |
07:29am |
MT |
|
Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments |
07:25am |
DJ |
|
Eli Lilly Q1 Non-GAAP Earnings, Revenue Rise; 2025 Earnings Guidance Trimmed |
07:07am |
MT |
|
Eli Lilly beats Q1 profit estimates on strength of diabetes drug |
06:55am |
RE |
|
(LLY) Eli Lilly and Co. Forecasts Fiscal Year 2025 Adjusted EPS Range $20.78 – $22.28 |
06:48am |
MT |
|
Earnings Flash (LLY) Eli Lilly and Co. Posts Q1 Revenue $12.73B, vs. FactSet Est of $12.67B |
06:48am |
MT |
|
Earnings Flash (LLY) Eli Lilly and Co. Posts Q1 Adjusted EPS $3.34, vs. FactSet Est of $3.26 |
06:47am |
MT |
|
Eli Lilly and Company Reports Earnings Results for the First Quarter Ended March 31, 2025 |
06:45am |
CI |
|
Eli Lilly and Company Reaffirms Earnings Guidance for the Year 2025 |
06:45am |
CI |
|
Equity Markets Close Higher Despite Weak Labor, Consumer Confidence Signals |
Apr. 29 |
MT |
|
Sector Update: Consumer Stocks Rise in Late Afternoon |
Apr. 29 |
MT |
|
Sector Update: Consumer |
Apr. 29 |
MT |
|
Top Midday Gainers |
Apr. 29 |
MT |
LLY: Dynamic Chart
Eli Lilly and Company is one of the world’s leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
– endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
– oncology (19.4%);
– immunology diseases (9.8%);
– neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
– other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
More about the company
Buy
Last Close Price
898.95USD
Average target price
991.97USD
Spread / Average Target
+10.35%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
